{"id":"NCT00699140","sponsor":"Instituto Grifols, S.A.","briefTitle":"Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura","officialTitle":"Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2008-06-17","resultsPosted":"2016-02-08","lastUpdate":"2016-02-08"},"enrollment":18,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Immune (Idiopathic) Thrombocytopenic Purpura"],"interventions":[{"type":"BIOLOGICAL","name":"IGIV3I Grifols","otherNames":["IGIV"]}],"arms":[{"label":"1 treatment group with IGIV3I Grifols","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.","primaryOutcome":{"measure":"Responder Patients","timeFrame":"At any time during the study period (The platelet count was measured at Days 1-6, 10, 14. 21, 30, 60, 90).","effectByArm":[{"arm":"1 Treatment Group With IGIV3I","deltaMin":72.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["Russia","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":18},"commonTop":["Petechiae","Ecchymosis","Headache","Pyrexia","Rash"]}}